A new live respiratory syncytial virus (RSV) vaccine holds promise against the infection, suggests a recent trial.
- RSV seronegative children between 6 and 24 months of age were given either intranasal doses of a placebo of RSV cold-passage/stabilized 2 (RSVcps2) vaccine, a previously studied product that was altered with mutations to stabilize it against diattenuation.
- 85% of the children were RSVcps2, 77% shed vaccine virus, and 59% developed at least a 4-fold increase in neutralizing antibody titers.
- Placebo and vaccine recipients both experienced a 50% rate of respiratory tract, febrile illness, or both.
Buchholz UJ, Cunningham CK, Muresan P, et al. Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. [Published online ahead of print March 2, 2018]. J Infect Dis. doi:10.1093/infdis/jiy066.
This Week's Must Reads
Do PCPs Recommend Medical Marijuana to Patients?, J Am Board Fam Med; 2018 Sep-Oct; Kondrad, et al
Intake of Sugars and Saturated Fats in US Children, Am J Clin Nutrit; ePub 2018 Sep 20; Wang, et al
Impact of Opioid Controlled Substance Agreements, Mayo Clin Proc; ePub 2018 Sep 20; Philpot, et al
MDD Screening Remains Low in Adolescents , J Pediatr; ePub 2018 Sep 21; Sekhar, et al
Subjective Wellbeing and Cardiometabolic Health, BMJ; ePub 2018 Sep 25; Wootton, et al
Must Reads in Vaccines
AAP Revision on Dismissing Vaccine-Refusing Families, JAMA Pediatr; ePub 2018 Apr 30; Deem, et al
Creating Preventive Vaccines for Lynch Syndrome, JAMA Oncology; ePub 2018 Apr 16; Chang, et al
Children with Autism Less Likely to Be Vaccinated, JAMA Pediatr; ePub 2018 Mar 26; Zerbo, et al
Antibody-Based Vaccines & Intracellular Pathogens, Curr Opin Immunol; ePub 2018 Apr 25; Casadevall
Designing an Effective Hepatitis C Vaccine, Trends Microbiol; ePub 2018 Apr 24; Kinchen, et al